News

Edge Therapeutics, a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today announced that Edge…
Read More...

Regen BioPharma has identified three new series of compounds that activate NR2F6. These compounds are small molecules and were identified using Regen's patented screening methodology…
Read More...

MyoKardia appoints David Meeker, as M.D to the Company’s board of directors. Dr. Meeker is executive VP and head of Sanofi Genzyme, the specialty care global business unit of Sanofi…
Read More...

Mateon announced that from its first schedule analysis from ongoing phase 2/3 Study(FOCUS) in patients with Platinum-resistant Ovarian Cancer result Positive. The analysis was…
Read More...

The US Food and Drug Administration (FDA) has scheduled Puma Biotechnology’s New Drug Application (NDA) for neratinib for discussion by the Oncologic Drugs Advisory Committee (ODAC) on…
Read More...

Roche interim results from the phase III HAVEN 2 study shows emicizumab prophylaxis showed a clinically meaningful reduction in the number of bleeds in children less than 12 years of…
Read More...

Prometic Life Sciences announced that it has received approval from FDA on the design of the first of its PBI-4050 planned phase 2/3 clinical trials for IPF based on the efficacy data…
Read More...

Ionis Pharmaceuticals announced its collaboration and license agreement with Suzhou Ribo Life Science Co., Ltd. (Ribo) to develop and commercialize RNA-targeted therapeutics in China.…
Read More...

RXi Pharmaceuticals announced that Gerrit Dispersyn, Dr. Med Sc. has been appointed as RXi's Chief Development Officer effective April 24, 2017. RXi's current Chief Development…
Read More...

Rigel Pharmaceuticals announced that it has submitted a NDA (New Drug Application) to the U.S. Food and Drug Administration (FDA) for fostamatinib in patients with chronic and…
Read More...

Allergan announced that it has entered into a clinical trial agreement with Novartis to conduct a Phase 2b study, using Allergan's cenicriviroc (CVC) and Novartis' lead FXR agonist for…
Read More...

Pilgrim Quality Solutions announced that Inovio Pharmaceuticals has selected Pilgrim to support its quality automation initiatives at its manufacturing and administrative sites and…
Read More...

Grifols will donate a minimum of 140 million international units (IU) of blood clotting factor medicines (Factor VIII) to the World Federation of Hemophilia (WFH) Humanitarian Aid…
Read More...

Zymeworks announced that its lead product candidate, ZW25, has been granted orphan drug designation from the U.S. Food and Drug Administration (the “FDA”) in the treatment of gastric…
Read More...

Immune Therapeutics a clinical-stage biopharmaceutical company developing therapies for a range of conditions using Lodonal, its proprietary formulation of lower-dose naltrexone,…
Read More...

Biocryst announced that it has received approvals from Europe's initial regulatory to explore a new Oral liquid formulation of BCX7353 for the treatment of Acute attacks in patients…
Read More...

Novartis announced that it has it has it has exercised an option to in-license ECF843 for ophthalmic indication worldwide to strengthen R&D pipeline. The closing of the deal is…
Read More...

GE Healthcare and CBMG (Cellular Biomedicine Group) collaborated to co-develop certain industrial control processes in CAR-T (Chimeric Antigen Receptor T-cell) and stem-cell…
Read More...

Digital diabetes management platform GlucoMe announced the appointment of John Erickson as EVP, General Manager North America. In this role, John will be responsible for leading the…
Read More...

Abbott and Alere announced that the companies have agreed to amend the existing terms of their agreement for Abbott's acquisition of Alere. Under the amended terms, Abbott will…
Read More...